Steroids, salt supplements, and birth control are some of the treatment options for this condition. Learn more about what they do and the potential side effects.

While Spruce Biosciences Inc.’s tildacerfont missed its phase II primary endpoint in classic congenital adrenal hyperplasia (CAH) last March, the U.S. FDA approved Crenessity (crinecerfont) from ...

No consistent clinically important trends were observed across key safety parameters, including clinical safety laboratory values, physical examination ... is currently in development for congenital ...

WASHINGTON, D.C. — The U.S. Food and Drug Administration (FDA) has approved Crenessity (crinecerfont) for use alongside glucocorticoids in managing classic congenital adrenal hyperplasia (CAH ...

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, announced positive topline results from an open-label, phase 2 congenital adrenal hyperplasia (CAH ... clinical safety ...